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Abstract
Men who enter active surveillance because their biopsy exhibits only Gleason grade 3 (G3) 
frequently have higher grade tumor missed by biopsy. Thus, biomarkers are needed that, when 
measured on G3 tissue, can predict the presence of higher grade tumor in the whole prostate. We 
evaluated whether PTEN loss, chromosome 8q gain (MYC) and/or 8p loss (LPL) measured only 
on G3 cores is associated with un-sampled G4 tumor. A tissue microarray was constructed of 
prostatectomy tissue from patients whose prostates exhibited only Gleason score 3+3, only 3+4, or 
only 4+3 tumor (n=50 per group). Cores sampled only from areas of G3 were evaluated for PTEN 
loss by immunohistochemistry, and PTEN deletion, LPL/8p loss, and MYC/8q gain by 
fluorescence in situ hybridization (FISH). Biomarker results were compared between Gleason 
score 6 vs. 7 tumors using conditional logistic regression.
PTEN protein loss, odds ratio=4.99, p=.033, MYC/8q gain, odds ratio=5.36, p=.010, and LPL/8p 
loss, odds ratio=3.96, p=.003 were significantly more common in G3 cores derived from Gleason 
7 vs. Gleason 6 tumors. PTEN gene deletion was not statistically significant. Associations were 
stronger comparing Gleason 4+3 vs. 6 than for Gleason 3+4 vs. 6. MYC/8q gain, LPL/8p loss, and 
PTEN protein loss measured in G3 tissue microarray cores strongly differentiate whether the core 
comes from a Gleason 6 or Gleason 7 tumor. If validated to predict upgrading from G3 biopsy to 
prostatectomy these biomarkers could reduce the likelihood of enrolling high risk men and 
facilitate safe patient selection for active surveillance.
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 Introduction
Increasing recognition of over-treatment of prostate cancer has stimulated use of active 
surveillance as a management strategy in select men with low grade, low volume prostate 
cancer (1, 2). For many active surveillance programs a key eligibility criterion is biopsy 
Gleason score 6 or less with no Gleason Pattern 4 tumor. However, studies of men with low 
risk tumors who were eligible for active surveillance but instead opted for immediate 
prostatectomy have shown that standard 12 core biopsy misses higher grade tumor in 25–
35% of cases with only Gleason 6 on biopsy (1, 3, 4). Because active surveillance programs 
generally perform surveillance (repeat) biopsies on a regular basis, most men under-sampled 
by the initial biopsy are subsequently detected with higher grade disease and offered curative 
treatment. Most of these men are found to have Gleason 3+4 tumors at surgery, and have a 
high probability of cure. However, in 17–32% of these cases Gleason 4+3 or 4+4 (or higher) 
tumors are found upon prostatectomy, and it is not known if the delay in treatment of such 
cases compromises the chance of cure (5–7).
Currently, there is a lack of data on biomarkers that consistently show an association with 
Gleason upgrading from biopsy to radical prostatectomy. We and others have shown that 
alterations in PTEN (protein or copy number alteration), MYC/8q, and LPL/8p are 
consistently associated with both higher Gleason score tumors, and increased risk of 
progression or death after prostatectomy (8–18). In particular, we recently showed that 
PTEN loss is associated with upgrading from Gleason 6 to 7 (19).
Because of the consistency with which PTEN loss and chromosome 8p/8q alterations have 
been associated with aggressive prostate cancer phenotype, they may have potential for 
identifying men who appear eligible for active surveillance (i.e. biopsy Gleason 6) but who 
actually harbor higher grade tumor that was not detected by biopsy. Since active surveillance 
is most often restricted to men with only Gleason pattern 3 on biopsy, the ideal tissue 
biomarker would be able to indicate the presence of unsampled pattern 4 in the prostate 
when measured on biopsy cores exhibiting only Gleason pattern 3. Therefore, we evaluated 
whether measurement of PTEN gene or protein, chromosome 8q (MYC) gain, 8p (LPL) loss 
in Gleason grade 3 (G3) tumor cores could distinguish those that came from Gleason 3+3=6 
vs. Gleason 3+4 or 4+3=7 tumors.
 MATERIALS AND METHODS
All biomarker analyses for the primary analyses were measured only on the G3 component 
of Gleason 6 or Gleason 7 tumors.
 Study subjects
Records were reviewed retrospectively for men who underwent radical prostatectomy at 
Johns Hopkins Hospital from 2001–2009 to identify those with available paraffin-embedded 
Trock et al. Page 2
Mod Pathol. Author manuscript; available in PMC 2016 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
tumor tissue whose prostatectomy specimen exhibited only a single Gleason score, i.e. either 
Gleason 3+3 only, 3+4 only, or 4+3 only. The protocol was approved by the Johns Hopkins 
Institutional Review Board. Cases were graded according to ISUP 2005 (20). Year of 
surgery was restricted to ensure that no specimens had been stored for more than 10 years at 
the time of biomarker analyses. Tumors from men with Gleason 3+3 were identified and 
matched by age at surgery (±5 years; median 2 years), year of surgery (±3 years; median 1 
year), and race to one case of Gleason 3+4 and one case of Gleason 4+3. Fifty men were 
selected in each of the 3 Gleason score categories. All tumors had to have adequate tumor 
volume to accommodate removal of 4 × 0.6 mm tissue cores. Also, cases of 3+3=6 tumor 
were excluded if there was any tertiary Gleason pattern 4.
 Tissue microarray construction
For each patient, four 0.6 mm cores of tumor nodule and four 0.6 mm cores of surrounding 
benign prostate tissue were manually punched and assembled into a 20 × 20 spot tissue 
microarray using a Beecher microarrayer as previously described (21). For Gleason 7 tumors 
cores were sampled from both G3 and G4 areas of tumor (Fig. 1). Matched sets (Gleason 
3+3, 3+4, 4=3) were placed on the same tissue microarray block, ensuring that comparison 
groups were processed identically, thus avoiding bias due to batch effects. In cases with 
Gleason pattern 4, all cores were obtained from separate areas of Gleason pattern 3 and 
Gleason pattern 4 from “index” tumors (e.g. the largest and highest grade tumor in the 
prostate) that contained both patterns. In other words, the Gleason pattern 3 and 4 were 
spatially adjacent and part of the same overall tumor nodule. Formalin-fixed and paraffin-
embedded cell lines with and without targeted disruption of both PTEN alleles were used as 
positive and negative controls for immunohistochemistry (12). Additionally, benign tissues 
from a variety of organs were also included as positive controls for staining.
 PTEN immunohistochemistry
PTEN immunohistochemistry was performed manually as previously described (12) on 4 
µm tissue microarray sections using a rabbit monoclonal α-PTEN antibody (clone D4.3, Cell 
Signaling Technologies). Tissue microarray slides were scanned using the Aperio 
ScanScope® CS virtual slide scanner (Aperio, Vista, CA) and composite tissue microarray 
core images were viewed using the TMAJ software package (http://
tmaj.pathology.jhmi.edu). Scoring of PTEN expression in tumor cells was performed by 2 
pathologists (ADM and BG), blinded with respect to FISH results, pathologic stage, and 
final Gleason score at radical prostatectomy, as well as patient outcome. PTEN protein was 
visually scored using a dichotomous system (12, 14), and classified as lost if the intensity 
was markedly decreased or entirely negative across all tumor cells compared with the 
surrounding benign glands and/or stroma. Each individual patient was classified as markedly 
decreased for PTEN if any of his tumor spots were classified as markedly decreased. Cases 
heterogeneous for PTEN loss, in which some tumor cells stained positive while others 
showed loss within the same core, were recorded as having PTEN loss if >10% of tumor 
cells within the core were negative or markedly decreased (12). Inter-observer 
reproducibility for this scoring system (e.g. diagnosing a given core with PTEN loss or not) 
has been shown to be excellent (12) and in the current study was 95% for all cores with 
cancer.
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 PTEN fluorescence in-situ hybridization (FISH)
From the same tissue microarray blocks used for PTEN protein and chromosome 8 FISH, 5 
sections of 5-μm thickness were cut for FISH analysis. Hematoxylin and eosin (H&E) 
sections were also cut before and after the sections for FISH and reviewed to insure the 
sections contained cancer and identify regions of interest. FISH analysis was performed on 
deparaffinized sections using PTEN and centromere 10 probe kits (Abbott Molecular, Des 
Plaines, IL). Sixty representative nuclei from the invasive tumor were scored by a trained 
cytogenetic technologist with overall evaluation by one of us (RBJ). Abnormal criteria were 
established though evaluation of 93 normal prostate biopsies included on the tissue 
microarrays as well as evaluation of the distribution of signal patterns among prostate cancer 
biopsies on the arrays. PTEN gene loss was defined as PTEN/CEN10 ratio <0.8 and ≥60% 
of cells enumerated with 0–1 PTEN signals. Cases were further categorized as having 
homozygous PTEN deletion if >10% of nuclei had 0 PTEN signals. The remaining cases 
were classified as hemizygous PTEN gene deletion. Cases with PTEN homozygous and 
hemizygous gene deletion typically had PTEN/CEN10 ratios <0.60 and >0.60/<0.80, 
respectively. Some cases had gain or loss of a whole chromosome 10. Gain of chromosome 
10 required >30% nuclei with 3 or more PTEN and CEN10 signals. Loss of a whole 
chromosome 10 required >60% of nuclei with 1 PTEN and CEN10 signals. Rare cases had 
two PTEN signals and three CEN10 signals. Such cases were classified as hemizygous 
PTEN gene deletion.
 Chromosome 8q and 8p alterations (FISH)
The method for LPL and MYC FISH has been previously described in detail (8). Briefly, 
dual-probe hybridization was performed on tissue microarrays using a centromere 8 probe 
[chromosome enumeration probe 8 (CEP8); Abbott Molecular, Des Plaines, IL] together 
with a locus specific probe. An 8p22 probe (LPL gene; Abbott Molecular) and 8q24 probe 
(MYC gene; Abbott Molecular) were the locus specific probes. Abnormal criteria were 
established through evaluation of normal biopsies included on the tissue microarrays. These 
normal values were similar to those reported by Tsuchiya (8). The copy number status of 
8p22, 8q24, and CEP8 in a tissue microarray biopsy was classified as normal, gain, 
duplication or loss. A case was classified as normal if <30% of nuclei had 3 or more signals 
and <60% of nuclei had 0 or 1 signal for all the probes. LPL was classified as loss if the 
LPL/CEP8 ratio was <0.85 or if 60% or more nuclei had 0 or 1 LPL signal. MYC was 
classified as gain if 30% or more nuclei had 3 or more MYC probe signals. For the MYC 
gene duplication category, in addition to the gain criteria, it was necessary that the overall 
mean MYC/CEP8 ratio be >1.3. If both LPL and CEP8 were lost and MYC was normal, 
MYC was classified as having relative gene duplication.
 Statistical analysis
The primary endpoint was prostatectomy Gleason 6 vs. Gleason 7 (3+4 and 4+3 combined). 
The primary analyses evaluated whether G3 cores from Gleason 7 tumors were more likely 
than G3 cores from Gleason 6 tumors to exhibit PTEN protein loss (immunohistochemistry), 
PTEN gene deletion (FISH), LPL/8p gene loss or MYC/8q gene gain (FISH). For most 
analyses, PTEN hemizygous or homozygous gene deletion were combined, and MYC/8q 
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gain or duplication were combined. Analyses were done with the patient as unit of analysis, 
i.e. a patient was classified as having the specified biomarker alteration (“high risk” status) if 
any of his G3 tumor cores exhibited the high risk alteration; otherwise he was classified as 
“normal” for that biomarker. The sample size was selected to provide power ≥80% to detect 
a minimum increase of 20% in the prevalence of PTEN protein loss (immunohistochemistry) 
in Gleason 7 tumors, assuming that the prevalence was ≤10% in Gleason 6 tumors. 
Descriptive characteristics were compared among Gleason 3+3, 3+4, and 4+3 using analysis 
of variance with blocking on matched set, or Mantel-Haenszel chi-square test for continuous 
and categorical variables, respectively. We compared the status of each biomarker to Gleason 
7 vs. 6 using conditional logistic regression to accommodate matched sets of GS3+3, 3+4, 
and 4+3. A secondary analysis compared Gleason 6 separately to Gleason 3+4 and to 
Gleason 4+3. All analyses were performed using SAS v9.3 (SAS Institute, Cary, NC).
 RESULTS
There were 50 men in each of the three Gleason score categories (6, 3+4, 4+3), matched on 
age (±5 years; median 3 years), and year of surgery (±3 years; median 1 year). Of these, 142 
(95%) had at least 1 core of G3 tumor that was informative for all four candidate 
biomarkers; these 142 men formed the basis for analysis.
The characteristics of men in each of the 3 Gleason score groups are shown in Table 1. As 
expected, both PSA and prostatectomy stage increased significantly with Gleason score. 
When evaluated only in G3 cores, PTEN protein loss (by immunohistochemistry), MYC/8q 
gene gain and LPL/8p gene loss (both by FISH) increased significantly with Gleason score, 
but the association with PTEN gene deletion was not statistically significant, although 
deletion appeared more frequent among Gleason 4+3 patients. Fig. 2A shows the trend 
between expression of each biomarker with increasing Gleason score. One or more high risk 
biomarker alterations were present in G3 cores from 23% of Gleason 3+3 tumors vs. 63% of 
Gleason 3+4 tumors vs. 72% of Gleason 4+3 tumors, p<0.0001 for trend. If Gleason score 
was dichotomized to 6 vs. 7 the association with PTEN protein loss, MYC/8q gene gain, and 
LPL/8p gene loss remained significant (p=0.01, <0.0001, <0.0001, respectively), while the 
association with PTEN gene deletion was not statistically significant (p=0.538) (data not 
shown). None of the four biomarkers were significantly associated with race, age, PSA, PSA 
density, number of positive biopsy cores, body mass index, or year of surgery (data not 
shown), with the exception of a significant decrease in age associated with MYC/8q gain, 
p=0.021. PTEN protein loss and LPL/8p gene loss were significantly associated with worse 
clinical stage, p=0.002 and .006, respectively. PTEN protein loss was significantly correlated 
with PTEN gene deletion, p<0.0001, and LPL/8p loss, p=0.001, but not with MYC/8q gain, 
p=0.386 (Table 2).
In univariate logistic regression analyses, PTEN protein loss, MYC/8q gene gain, and 
LPL/8p gene loss in a G3 core were associated with a statistically significant 4 to 5-fold 
increase in the odds that the tumor was Gleason 7 vs. Gleason 6, but PTEN gene deletion 
(hemizygous or homozygous deletion) was not statistically significant (Table 3). In 
multivariable models MYC/8q gain and LPL/8p loss, or MYC/8q gain and PTEN protein 
loss were independently predictive (both models are considered because the strong 
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collinearity between PTEN protein loss and LPL/8p gene loss makes it questionable to 
evaluate both variables in the same model) (22). Adjustment for age, PSA, clinical stage, 
number of positive biopsy cores, body mass index, or year of surgery did not change the 
association between biomarkers and prostatectomy Gleason score (data not shown), so only 
the biomarker results are shown. We also evaluated the impact of having alteration in more 
than one biomarker. Compared to having no biomarker alterations, having 1, 2, or 3–4 
different biomarker alterations in a G3 core was associated with increased likelihood of a 
Gleason 7 tumor, odds ratio=6.04 (p=.003), 9.26 (p=.002), or 10.04 (p=0.015), respectively 
(data not shown). Forty-one patients (29%) had 2 or more different biomarker alterations in 
a G3 core.
In secondary analyses, models were separately constructed with Gleason 6 vs. 3+4, and 
Gleason 6 vs. 4+3 (Table 4). For all 4 biomarkers, associations were stronger with Gleason 
4+3 than with Gleason 3+4. For Gleason 3+4, only the association with MYC/8q gain was 
statistically significant, although all but PTEN gene deletion show elevated odds ratios. In 
contrast, for Gleason 4+3, PTEN protein loss, MYC/8q gain, and LPL/8p loss all show 
significant positive associations. We also evaluated whether the likelihood of a Gleason 7 
tumor increased with the number of G3 cores or percentage of G3 cores exhibiting 
biomarker alteration. Using either metric there was a significant association between 
increased “dose” of cores with MYC/8q gain or LPL/8p loss and likelihood that the cores 
came from a Gleason 7 tumor. In contrast, having more than one core with PTEN protein 
loss did not increase the risk of a Gleason 7 tumor beyond the increase observed for one core 
(data not shown).
Considering all cores (G3 and G4) from patients with Gleason 7 tumors we evaluated 
whether biomarker alteration in a G3 core occurred more commonly when the alteration was 
also present in one of the matched G4 cores. Among tumors with a biomarker alteration in at 
least 1 G3 core, 65–78% of tumors also had the alteration in at least one of the matching G4 
cores (Figure 2B). These data indicate that alterations in these candidate biomarkers in 
Gleason 7 tumors rarely occur in G3 glands without concomitant alteration in the G4 glands.
 DISCUSSION
Most current protocols for active surveillance depend on biopsy pathology as a major 
determinant of eligibility, with detection of Gleason G4 frequently indicating the need for 
treatment rather than surveillance. A limitation of these protocols is that needle biopsy 
underestimates tumor grade in 25–35% of cases, and in such cases, the true grade may 
require several rounds of surveillance (follow-up) biopsies before it is revealed or it may be 
missed altogether (23). Until a signature of aggressive phenotype independent of Gleason 
grade is developed, biomarkers that can indicate if a biopsy G3 is associated with un-
sampled G4 tumor would be a major improvement in our ability to safely assign men to 
active surveillance. In this study we have demonstrated that a G3 core that exhibits PTEN 
protein loss, MYC/8q gene gain or LPL/8p gene loss is much more likely to have come from 
a Gleason 7 than Gleason 6 tumor, and that the association is even stronger for Gleason 4+3 
than 3+4 tumors. PTEN hemiozygous or homozygous gene deletion appeared to be 
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somewhat more common in G3 cores from Gleason 7 tumors, but the difference was not 
statistically significant.
Our findings suggest that occurrence of these biomarker alterations in G3 tumor foci is a 
strong indicator of the likely presence of adjacent G4 tumor that was not sampled by the 
biopsy, and thus, a more aggressive phenotype than expected for a purely pattern 3 histology. 
Furthermore, we observed that, in Gleason 7 tumors, biomarker alteration in G3 glands is 
much more likely when the matching G4 glands also exhibit the alteration. These findings 
are consistent with a recent study that sequenced TMPRSS2 and ERG loci from Gleason 
3+4 tumors from four patients whose tumors exhibited a TMPRSS2-ERG fusion event, and 
found that adjacent G3 and G4 tumor foci exhibited identical breakpoints, indicating that the 
two Gleason patterns were clonally related (24). In two cases, there was loss of one PTEN 
allele in both components, yet the Gleason G4 tumor showed loss of both PTEN alleles (24). 
This finding suggested that, at least at times, a Gleason pattern 4 tumor may clonally evolve 
from the adjacent Gleason pattern 3 lesion or that they both came from a common precursor 
lesion and PTEN gene deletion may be a characteristic of such molecular progression (24). 
Kovtun et al., also found by next generation sequencing that tumors with mixed G3 and G4 
also showed strong evidence of a clonal relationship (25). Our study does not address the 
question of whether a G3 only lesion that was remotely located in the prostate away from 
any G4 lesion would also have an increased prevalence of PTEN loss, 8p loss or 8q24 gain. 
Future studies are required to address this important question.
There has been little evaluation of PTEN as a predictor of aggressive phenotype in patients 
managed by (or eligible for) active surveillance, and we are not aware of studies that have 
evaluated MYC/8q or LPL/8p in such patients. In a Swedish watchful waiting cohort, a 
signature associated with embryonic stem cells, p53 mutation or inactivation, and PTEN loss 
was strongly associated with higher Gleason grade, and with a 3-fold increase in risk of 
death (26). In transurethral resection of the prostate specimens from 675 men managed 
conservatively, Cuzick et al. observed PTEN protein loss was significantly more prevalent in 
Gleason 7 (20%) than Gleason 6 tumors (3%) (16). Although not managed conservatively, a 
small series comparing tumors classified as clinically insignificant according to Epstein 
criteria (i.e. Gleason 6, <3 cores positive, ≤50% of any core involved with tumor; the same 
criteria used by many institutions to define eligibility for active surveillance) vs. clinically 
significant tumors (predominantly Gleason ≥7), PTEN protein loss was observed in 0/7 
insignificant tumors vs. 8/19 significant tumors (27).
We believe this is the first proof of concept demonstration that biological characteristics of 
the Gleason pattern 3 component of a Gleason score 7 tumor are distinctly and significantly 
different than that of a Gleason score 6 tumor, indicating that biopsy Gleason 6 can at times 
be misleading. The results imply that interrogation of molecular features within a Gleason 6 
biopsy can augment the ability of standard Gleason grading by traditional histopathology to 
predict overall prostate pathology. Indeed, in a recent study, members of our group showed 
that PTEN protein loss in Gleason 6 biopsies was much more common in tumors that were 
upgraded to Gleason 7 at prostatectomy compared to tumors that remained Gleason 6 at 
prostatectomy (19). If replicated in additional studies, these results may stimulate a 
widespread change in practice to include PTEN immunohistochemistry in apparently low 
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volume Gleason 6 tumors to help determine appropriateness for active surveillance. Further 
studies using prostate needle biopsies to measure all 3 biomarkers from the present study are 
clearly warranted.
It is not clear why PTEN gene deletion by FISH did not correlate with increased Gleason 
score, while PTEN protein loss by immunohistochemistry did. Although PTEN gene 
deletion by FISH did correlate with PTEN protein loss in a highly significant matter 
(P<0.0001), there were still several discrepancies between these, especially at the individual 
core level. The largest discrepancy was when PTEN protein was markedly decreased by 
immunohistochemistry but there was no apparent loss by FISH (21 of 58 discrepant spots; 
36%). We and others have previously shown that in 30–40% of cases with PTEN 
immunohistochemistry loss, there is no underlying PTEN gene deletion detected by FISH 
(12, 28). The simplest explanation is that, while PTEN protein loss in prostate cancer occurs 
almost always by deletion (and not point mutations for example), the deletions can be quite 
small and many of these may not be picked up by the relatively large PTEN FISH probe 
used in our assay. It is not clear how our results may differ if we use the newer four-color 
PTEN FISH probes, which are suggested to be more sensitive and specific for finding PTEN 
deletions than a two color approach (29, 30). Discrepancy between immunohistochemistry 
and FISH could also arise if assessment of FISH was performed in a different area than was 
lost by immunohistochemistry. This could result in cases in which PTEN protein loss by 
immunohistochemistry is heterogeneous in the tumor core, yet is easily recognized; 
however, if the part of the core that was not lost by immunohistochemistry was counted by 
FISH, the case would be likely recorded as having no FISH abnormality. In 9 tissue 
microarray spots, FISH scoring indicated a homozygous deletion yet there was no protein 
loss recorded by immunohistochemistry. There appeared to be a number of potential reasons 
for this, perhaps the most important of which is that PTEN immunohistochemistry can be 
difficult to interpret in a small percentage of cases. Although there was 95% concordance in 
PTEN calls by different observers in the current study overall, in some cores (including 3/9 
of the above-described cores), different observers scored the immunohistochemistry 
differently, indicating that these cores were difficult to call by immunohistochemistry. In one 
core, there was a clear decrease in immunohistochemistry staining, however, this was not 
enough to reach a threshold for calling the core markedly decreased. We have shown 
previously that the specificity of immunohistochemistry staining using this assay is 
extremely high (e.g. ≥95% for mutant cell lines (12)) so it is unlikely that a significant 
fraction of cores would be misclassified as positive staining when indeed there is no PTEN 
protein present.
The study has a number of strengths, including matching of Gleason 6 and 7 tumors on age, 
race, and year of surgery, use of well-validated assays, high quality tissue microarray 
constructed with tumor samples that exhibited only a single Gleason score and were <10 
years old, and inclusion of multiple cores from each grade component. However, there are 
some limitations. First, the biomarkers were assayed in tissue microarray cores taken from 
prostatectomy specimens, not biopsies. Although targeted sampling of the index tumor by 
this approach is an imperfect model of the relatively blind sampling conducted with typical 
transrectal ultrasound biopsies, it may be a reasonable model of the type of targeted 
sampling that is becoming increasingly available with MRI-guided biopsies. However, it is 
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clear that additional validation of the joint utility of these biomarkers in a series of biopsies 
from active surveillance patients is necessary to determine whether biomarker alterations in 
Gleason 3+3=6 biopsies are more common in patients who are upgraded to Gleason ≥7 
during follow-up or surgery. These studies in biopsy specimens are ongoing. Second, since a 
combination of MRI-ultrasound fusion guided biopsies with standard systematic biopsies 
increases the ability to identify tumors with Gleason 7 and higher (31–33), future studies 
employing the biomarkers herein along with MRI-guided biopsies should be performed to 
determine the relative value of each; in particular, whether these biomarkers add prognostic 
information beyond Gleason. Third, the sample size of 142 patients is moderate, and only a 
relatively small percentage of patients exhibited PTEN protein loss (15%), PTEN gene 
deletion (14%), and MYC/8q gain (20%). The cohort size and use of only recent cases 
limited the ability to evaluate clinical outcomes such as biochemical recurrence or 
metastasis. However, ample data from other studies demonstrate that these biomarker 
alterations are prognostic for clinical outcomes. Furthermore, associations we observed 
between biomarker status and grade were not modified by adjustment for other relevant pre-
surgical prognostic features.
 CONCLUSIONS
PTEN protein loss, MYC/8q gain, or LPL/8p loss in a G3 tumor core is a strong indicator 
that the core comes from a Gleason 7 tumor, and occurs even more frequently in G3 cores 
from Gleason 4+3 than 3+4. Among Gleason 7 tumors, the predominance of these 
biomarker alterations in both the G3 and G4 cores provides additional evidence that such 
tumors may be clonally related in many cases. Further, the results suggest that histological 
Gleason pattern 3 sampled from a Gleason 7 cancer is often biologically distinct from 
Gleason pattern 3 from a Gleason 6 tumor. Combined with recent data showing that PTEN 
protein loss is more common in Gleason 6 tumors that are upgraded at prostatectomy (11, 
19, 30), and, showing that a PTEN immunohistochemistry assay based on our highly 
validated approach (12) can now be implemented readily in CLIA certified pathology 
laboratories using automated staining systems with a commercial anti-PTEN antibody (18) 
these results suggest that these biomarkers may have significant clinical utility for 
identifying men who are not suitable candidates for active surveillance.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A, Sampling scheme to select Gleason pattern 3 and Gleason pattern 4 tumor cores from 
matched cases of Gleason score 3+3, 3+4, and 4+3 for tissue microarray construction. B, 
Schematic of tissue microarray construction. Note that 4 cores from each Gleason pattern 
were selected for the tissue microarray.
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Figure 2. 
A, Frequency of PTEN protein loss, PTEN gene deletion, MYC/8q gene gain, and LPL/8p 
gene loss in Gleason pattern 3 cores from matched Gleason score 3+3, 3+4, and 4+3 tumors 
(n=142). B, Frequency of biomarker alteration in a grade 3 core is associated with biomarker 
alteration in at least 1 matched grade 4 core in Gleason score 7 tumors.
* Number of tumors with indicated biomarker alteration in a grade 3 core.
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Table 1
Characteristics of study participants, by prostatectomy Gleason score
Gleason Score
Characteristic (n) 6
(47)
3+4
(48)
4+3
(47)
p-value
Age, median (years) 61.0 60.0 60.0 0.746*
Year of surgery, median 2005 2005.5 2005 0.590*
Race, n (%) 1.000**
    Caucasian 46 (98) 47 (98) 46 (98)
    African-American 1 (2) 1 (2) 1 (2)
PSA, median (ng/ml) 4.4 5.1 6.5 0.0002*
Prostatectomy stage, n (%) <0.0001**
    organ-confined 40 (85) 29 (60) 20 (43)
    EPE 7 (15) 19 (40) 19 (40)
    SVI 0 (0) 0 (0) 4 (9)
    LNI 0 (0) 0 (0) 4 (9)
Surgical margin status, n (%) 0.242**
    Negative 41 (93) 36 (80) 38 (84)
    Positive 3 (7) 9 (20) 7 (16)
PTEN immunohistochemistry***, n (%) 0.005**
    Not decreased 45 (96) 40 (83) 35 (75)
    Markedly decreased 2 (4) 8 (17) 12 (26)
PTEN FISH***, n (%) 0.140
    Normal 42 (89) 43 (90) 37 (79)
    Hemizygous deletion 1 (2) 2 (4) 5 (11)
    Homozygous deletion 4 (9) 3 (6) 5 (11)
MYC/8q FISH***, n (%) 0.011**
    Normal/loss 43 (92) 37 (77) 33 (70)
    Gain/duplication 4 (9) 11 (23) 14 (30)
LPL/8p*** FISH, n (%) 0.0002**
    Normal/duplication 35 (75) 26 (54) 17 (36)
    Loss 12 (26) 22 (46) 30 (64)
Abbreviations: EPE, extra-prostatic extension; SVI, seminal vesicle involvement; LNI, lymph node involvement; FISH, fluorescence in-situ 
hybridization
*based on Kruskal-Wallis test
**based on Mantel-Haenszel chi-square test
***
Biomarker status based on Gleason grade 3 core only
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Table 3
Conditional logistic regression models of PTEN loss by immunohistochemistry, and PTEN deletion, 8q/MYC 
gain, and 8p/LPL loss by FISH* in grade 3 cores as predictors of Gleason score 7 vs. 6 (n=142)
Univariate Models
Biomarker Alteration Odds Ratio (95% CI) p-value
PTEN loss vs. normal
  (immunohistochemistry)
4.99 (1.14, 21.98) 0.033
PTEN deletion vs. normal (FISH) 1.44 (0.50, 4.18) 0.498
MYC/8q gain vs. normal (FISH) 5.36 (1.50, 19.09) 0.010
LPL/8p loss vs. normal (FISH) 3.96 (1.58, 9.94) 0.003
Multivariable Models
Biomarker Alteration Odds Ratio (95% CI) p-value
MODEL 1
PTEN loss vs. normal
  (immunohistochemistry)
5.21 (1.14, 23.76) 0.033
MYC/8q gain vs. normal (FISH) 5.78 (1.51, 22.06) 0.010
MODEL 2
MYC/8q gain vs. normal (FISH) 5.28 (1.35, 20.58) 0.017
LPL/8p loss vs. normal (FISH) 3.78 (1.46, 9.80) 0.006
Abbreviations: FISH, fluorescence in-situ hybridization; OR, odds ratio; CI, confidence interval.
*A patient was considered to have the specific biomarker alteration if any grade 3 core exhibited the change
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Table 4
Univariate logistic regression models of PTEN loss by immunohistochemistry, and PTEN deletion, 8q/MYC 
gain, and 8p/LPL loss by FISH* in grade 3 cores as predictors of Gleason score 3+4 vs. 6 (n=95), and Gleason 
score 4+3 vs. 6 (n=94)
Gleason 3+4 vs. 6 Gleason 4+3 vs. 6
Predictor variable OR (95% CI) p-value OR (95% CI) p-value
PTEN loss vs. normal 3.50 (0.73, 16.85) 0.118 5.50 (1.22, 24.80) 0.027
PTEN deletion** vs. normal 0.80 (0.22, 2.98) 0.739 2.67 (0.71, 10.05) 0.147
MYC gain vs. normal 8.00 (1.001, 63.96) 0.0499 6.00 (1.34, 26.81) 0.019
LPL loss vs. normal 2.60 (0.93, 7.29) 0.069 9.00 (2.09, 38.79) 0.003
Abbreviations: FISH, fluorescence in-situ hybridization; OR, odds ratio; CI, confidence interval.
*A patient was considered to have the specific biomarker alteration if any grade 3 core exhibited the change
Mod Pathol. Author manuscript; available in PMC 2016 October 15.
